2024 Second Extraordinary General Meeting of Shareholders Meeting Meeting Materials
Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Announcement on changes in accounting estimates
Announcement on the remuneration plan for the company\'s directors, supervisors and senior management
Announcement on joint capital increases and related transactions between the company and related parties to participating companies
Voluntary disclosure of the announcement regarding the subsidiary's active pharmaceutical ingredient obtaining a notice of approval for listing application.
Legal Opinion of Kangda Law Firm in Peking Regarding the First Extraordinary Shareholders' Meeting of Hunan Warner Pharmaceutical Co., Ltd. in 2024.
Announcement of the resolution of the first extraordinary Shareholders' Meeting in 2024.
Materials for the first extraordinary shareholder meeting in 2024.
Voluntarily disclose the announcement about the subsidiary passing the pharmaceutical GMP compliance inspection.
Notice of the First Extraordinary Shareholders' Meeting in 2024
Voluntary disclosure of the announcement regarding the subsidiary's active pharmaceutical ingredient obtaining a notice of approval for listing application.
Announcement regarding the issuance of subscription objects for this issuance and the issuance of a commitment letter to specific objects for the issuance of stocks by the company.
Announcement on requesting the approval of the shareholders' meeting to exempt the subscription subject from issuing a tender offer.
Announcement Regarding Punishments or Regulatory Measures Taken by Securities Regulatory Authorities and Exchanges in the Past Five Years
Voluntary disclosure of the announcement regarding the subsidiary's active pharmaceutical ingredient obtaining a notice of approval for listing application.
Voluntary Disclosure Notice Regarding Subsidiary Pharmaceuticals Obtaining Approval Notice for Marketing Applications
Voluntary Disclosure Notice Regarding Subsidiary Pharmaceuticals Obtaining Approval Notice for Marketing Applications
Announcement on cooperative investments with private equity funds
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
No Data
No Data